Oppenheimer & Co. Inc. lowered its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 13,210 shares of the company’s stock after selling 235 shares during the period. Oppenheimer & Co. Inc. owned about 0.21% of VanEck Pharmaceutical ETF worth $1,140,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the business. WT Wealth Management raised its stake in shares of VanEck Pharmaceutical ETF by 5.6% during the fourth quarter. WT Wealth Management now owns 56,690 shares of the company’s stock valued at $4,891,000 after acquiring an additional 3,030 shares during the last quarter. Blue Chip Partners LLC bought a new position in VanEck Pharmaceutical ETF during the fourth quarter worth $2,139,000. NTV Asset Management LLC raised its stake in VanEck Pharmaceutical ETF by 3.6% during the fourth quarter. NTV Asset Management LLC now owns 7,709 shares of the company’s stock worth $665,000 after buying an additional 271 shares during the last quarter. Activest Wealth Management bought a new position in VanEck Pharmaceutical ETF during the fourth quarter worth $32,000. Finally, Apollon Wealth Management LLC raised its stake in VanEck Pharmaceutical ETF by 14.2% during the fourth quarter. Apollon Wealth Management LLC now owns 32,708 shares of the company’s stock worth $2,822,000 after buying an additional 4,076 shares during the last quarter.
VanEck Pharmaceutical ETF Stock Down 0.6 %
Shares of NASDAQ PPH opened at $93.99 on Wednesday. VanEck Pharmaceutical ETF has a twelve month low of $84.48 and a twelve month high of $99.51. The firm has a fifty day simple moving average of $88.44 and a 200 day simple moving average of $91.40. The company has a market capitalization of $586.50 million, a PE ratio of 30.55 and a beta of 0.72.
VanEck Pharmaceutical ETF Increases Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- Trading Halts Explained
- GitLab: Get In While It’s Down—Big Rebound Ahead
- About the Markup Calculator
- Tesla Stock: Finding a Bottom May Take Time
- What is the S&P 500 and How It is Distinct from Other Indexes
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.